Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922555 · ClinicalTrials.gov registry record · Phase 1
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
A Phase 1 study of Neurological Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT03922555 is a Phase 1 study of Neurological Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 18 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT03922555, a Phase 1 study of Neurological Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
Conditions Studied
Interventions
- DRUG ASTX727
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-07-12 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922555
The ClinicalTrials.gov registry entry for NCT03922555 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurological Cancer appearing as the primary indexed condition, and to 1 intervention - of which ASTX727 is the first listed.
NCT03922555 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03922555 about?
NCT03922555 is a clinical study titled "ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas". this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
What is the current status of trial NCT03922555?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-07-12. Estimated completion is 2028-08-01.
What conditions does trial NCT03922555 study?
This clinical trial studies the following conditions: Neurological Cancer.
What interventions are being tested in trial NCT03922555?
The interventions under investigation include: ASTX727 (DRUG).
Who is sponsoring clinical trial NCT03922555?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922555 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurological Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.